Shopping Cart
- Remove All
Your shopping cart is currently empty
Ociperlimab
😃Good
Catalog No. T78324Cas No. 2342597-93-5
Alias BGB-A1217
Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2].
Ociperlimab
Ociperlimab
😃Good
Catalog No. T78324Alias BGB-A1217Cas No. 2342597-93-5
Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2]. |
| In vitro | Ociperlimab (BGB-A1217; 0-10 μg/mL) enhances the secretion of IFN-γ by cytomegalovirus-specific T cells, activates natural killer cells and monocytes in an Fc-dependent manner at 1-1000 ng/mL, and removes TIGIT from T cell surfaces via Fc-dependent endocytosis in vitro [1]. |
| In vivo | Ociperlimab (BGB-A1217; doses of 3 and 10 mg/kg; administered intraperitoneally) elicits antitumor efficacy through an Fc-dependent mechanism in CT26 WT and MC38 tumor-bearing humanized TIGIT-knockin mice [1]. |
| Alias | BGB-A1217 |
| Cas No. | 2342597-93-5 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ociperlimab | purchase Ociperlimab | Ociperlimab cost | order Ociperlimab | Ociperlimab in vivo | Ociperlimab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.